Stay updated on Extension Study of Lirentelimab in Eosinophilic Gastritis Clinical Trial
Sign up to get notified when there's something new on the Extension Study of Lirentelimab in Eosinophilic Gastritis Clinical Trial page.

Latest updates to the Extension Study of Lirentelimab in Eosinophilic Gastritis Clinical Trial page
- Check2 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a Phase 3 study for AK002 in patients with Eosinophilic Gastritis, including key inclusion and exclusion criteria, as well as the study director's name. A new version number has been added.SummaryDifference19%
- Check9 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check66 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
- Check74 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check88 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Extension Study of Lirentelimab in Eosinophilic Gastritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Extension Study of Lirentelimab in Eosinophilic Gastritis Clinical Trial page.